Similar Search Results

Group living for elderly patients with dementia -- A cost analysis

Svensson, Marianne; Edebalk, Per Gunnar; Persson, Ulf - In: Health Policy 38 (1996) 2, pp. 83-100

Persistent link: https://www.econbiz.de/10005516183

The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden

Willis, Michael; Svensson, Marianne; Löthgren, Mickael; … - In: The European Journal of Health Economics 11 (2010) 6, pp. 585-594

Persistent link: https://www.econbiz.de/10008775862

[Besprechung von:] Unga, Nils: Socialdemokratin och arbetslöshetsfrågan 1912-34

Edebalk, Per Gunnar - In: Economy and history 20 (1977) 1, pp. 52-56

Persistent link: https://www.econbiz.de/10002092598

Social insurance in Sweden

Edebalk, Per Gunnar; Elmér, Åke - In: Social insurance : papers presented at the 5. Arne Ryde …, (pp. 53-69). 1983

Persistent link: https://www.econbiz.de/10002092590

Samhällets ekonomi

Delander, Lennart; Edebalk, Per Gunnar - 1975 - 2. uppl

Persistent link: https://www.econbiz.de/10002064223

Samhällets ekonomi

Delander, Lennart; Edebalk, Per Gunnar - 1978 - Nyt utg

Persistent link: https://www.econbiz.de/10002064229

A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 10 (2012) 4, pp. 217-225

Sweden has experienced a national value-based pricing (VBP) system for innovative outpatient drugs operated by the Pharmaceutical Benefits Board — LFN (now called the Dental and Pharmaceutical Benefits agency — TLV) since 2002. VBP has the character of a monopoly system, leading to...

Persistent link: https://www.econbiz.de/10011000768

Authors’ Reply to Godman and Gustafsson: “A New Reimbursement System for Innovative Pharmaceuticals Combining Value-Based and Free Market Pricing”

Persson, Ulf; Svensson, Johanna; Pettersson, Billie - In: Applied Health Economics and Health Policy 11 (2013) 1, pp. 83-84

Persistent link: https://www.econbiz.de/10011000861

A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden

Persson, Ulf; Willis, Michael; Ödegaard, Knut - In: The European Journal of Health Economics 11 (2010) 2, pp. 195-203

Persistent link: https://www.econbiz.de/10009404141

Reimbursement and clinical guidance for pharmaceuticals in Sweden

Anell, Anders; Persson, Ulf - In: The European Journal of Health Economics 6 (2005) 3, pp. 274-279

Persistent link: https://www.econbiz.de/10009404270